Walleye Capital’s Gossamer Bio GOSS Stock Holding History

Walleye Capital’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-101	Closed	-$97K	–	3350
2022 Q3	$97K	Buy	+101	New	+$100K	﹤0.01%	2440
2020 Q2	–	Sell	-140	Closed	-$114K	–	759
2020 Q1	$114K	Buy	+140	New	+$146K	0.03%	575

Other funds holding GOSS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Walleye Capital's GOSS Position: Q1 2026 in Review

Walleye Capital sold out of Gossamer Bio (GOSS) in Q1 2026, closing a stake of 13,463 shares — an estimated $3.34M sold.

Walleye Capital first reported a position in GOSS in Q1 2020 and held it in 9 quarters. The position peaked at $4.66M in Q2 2022. 181 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

Walleye Capital reported no remaining Gossamer Bio position as of Q1 2026 after selling out during the quarter.
Walleye Capital sold 13,463 Gossamer Bio shares in Q1 2026, an estimated $3.34M.
Walleye Capital first reported a position in Gossamer Bio in Q1 2020 and held it in 9 quarters.
Walleye Capital's Gossamer Bio position peaked at $4.66M in Q2 2022.
181 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.